P rimary aldosteronism (PA) is the leading cause of secondary hypertension with a prevalence of 4.3% in the general hypertensive population and 9.5% of patients referred to hypertension units. 1 The diagnosis of PA is fundamental because these patients are at an increased risk of cardiovascular and cerebrovascular complications and metabolic syndrome compared with patients with primary hypertension and similar cardiovascular risk profiles. [2] [3] [4] [5] The underlying cause of PA in the majority of patients is either bilateral adrenal hyperplasia (BAH, also called idiopathic hyperaldosteronism) or unilateral aldosterone-producing adenoma (APA). These subtypes must be differentiated to permit a targeted therapeutic strategy: surgical removal of APA or pharmacological treatment of BAH with mineralocorticoid receptor antagonists. Adrenal venous sampling (AVS) is the gold standard to localize the source of aldosterone excess and to discriminate between unilateral and bilateral forms of the disease. However, AVS is a technically demanding and invasive procedure requiring a dedicated radiologist. The reliable differentiation of APA and BAH by an alternative technique could potentially circumvent the requirement of AVS in patients with BAH that account for around two thirds of all cases of PA. 6 Subsequently, for the APA subtype, both clinician and patient would be highly motivated to perform/undergo AVS to confirm unilateral PA and define the side of aldosterone excess before adrenalectomy.
occurring in KCNJ5. 8 A recent meta-analysis showed that the overall prevalence of KCNJ5 mutations was 43%, with 35% for Europe, the United States, and Australia compared with 63% in China and Japan. 9 Intriguingly, mutations in ATP1A1, ATP2B3, and CACNA1D that stimulate aldosterone production have been identified recently in aldosterone-producing cell clusters of normal adrenal glands from kidney donors; in contrast, mutations in KCNJ5 were not detected. 10 In this study, we used liquid chromatography-tandem mass spectrometry (LC-MS/MS) to determine the steroid profiles in adrenal venous (AV) and peripheral venous (PV) plasma samples in PA patients with confirmed lateralization of aldosterone production. Our aim was to identify distinct steroid fingerprints associated with APA genotype that could potentially have a wider clinical application for the selection of unilateral patients with PA to undergo AVS.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Patient Selection
The study was approved by the appropriate institutional ethics committees and all patients gave their written informed consent. The study comprised 79 APAs surgically removed from patients with unilateral PA diagnosed at 2 referral centers (68 from the Medizinische Klinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany and 11 from the Radboud University Medical Center, Nijmegen, The Netherlands). The diagnosis of PA was established according to Endocrine Society Guidelines 11 and specific details for PA diagnosis and AVS procedures are as described. 12, 13 Further details on AVS procedures are provided in the Methods section in the online-only Data Supplement.
DNA Sequencing of KCNJ5, ATP1A1, ATP2B3, and CACNA1D
DNA fragments of KCNJ5, ATP1A1, ATP2B3, and CACNA1D were amplified by polymerase chain reaction and sequenced as described. 8 The 79 patients comprised the following APA genotypes: 36 (45.6%) without a mutation in a candidate gene (32 from Munich and 4 from Nijmegen), that for the purposes of this study are referred to as wildtype; 27 (34.2%) KCNJ5 mutations (23 from Munich and 4 from Nijmegen); 9 (11.4%) ATPase mutations (6 from Munich [3×ATP1A1 and 3×ATP2B3] and 3 from Nijmegen [1×ATP1A1 and 2×ATP2B3]); and 7 (8.9%) CACNA1D mutations (all 7 from Munich).
Patient demographics and characteristics at study entry and postoperative follow-up according to mutational status are shown in Table  S1 in the online-only Data Supplement.
LC-MS/MS Steroid Profiling
Steroid profiling used LC-MS/MS to measure 15 adrenal steroids as described elsewhere 14 and are listed in Table S2 along with concentrations measured in peripheral plasma of 120 normotensive, healthy volunteers included as a reference group. Lateralization ratios for the different steroids were calculated as detailed in the online-only Data Supplement.
Statistical Analysis
Data are expressed as medians and interquartiles. Statistical analyses used the JMP statistics software package (SAS Institute Inc, Cary, NC). Further details of statistical tests are detailed in the expanded Methods section of this article.
Results
An expanded Results section is available in the online-only Data Supplement.
LC-MS/MS Steroid Profiles: AV Plasma
Concentrations of 18-oxocortisol were higher in the lateralized AV plasma from APAs with KCNJ5 mutations compared with wild-type (P<0.001), ATPase (P=0.015), and CACNA1D (P=0.003) groups (Table S3) , translating to 18-fold higher concentrations compared with all other groups combined together (P<0.001).
Concentrations of aldosterone, 18-hydroxycortisol, and 11-deoxycorticosterone were also higher (P<0.05) in the lateralized AV plasma from APAs with KCNJ5 mutations compared with wild-type (Table S3) .
Compared with all other groups combined, lateralized AV plasma concentrations of adrenal steroids were lowest in patients with APAs because of CACNA1D mutations.
AV Lateralization Ratios
AVS lateralization ratios were generally higher among patients with APAs because of KCNJ5 mutations compared with other groups and displayed variations that depended on whether they were calculated as a ratio to cortisol versus mean values for DHEA+androstenedione (Table 1) . By either method of calculation, lateralization ratios for aldosterone, 18-oxocortisol, and 18-hydroxycortisol among patients with APAs because of KCNJ5 mutations, respectively, averaged 2.4-to 3.3-fold higher (P<0.05), 3.9-to 5.0-fold higher (P<0.001), and 3.3-to 5.3-fold higher (P<0.0001) than those for other groups combined. Lateralization ratios for 11-deoxycorticosterone and corticosterone were also, respectively 3.2-to 5.0-fold higher (P<0.001) and 1.7-to 2.2-fold higher (P<0.005) among patients with APAs because of KCNJ5 mutations than for all other groups combined.
LC-MS/MS Steroid Profiles: PV Plasma
Patients with APAs carrying KCNJ5 mutations displayed 21-fold higher (P<0.05) PV concentrations of 18-oxocortisol compared with the wild-type group (Table 2 ) and a 16-fold higher (P<0.0001) concentration compared with that of all other groups combined together (Table S2) . PV concentrations of 18-hydroxycortisol were also higher (2.9-fold, P<0.05) among patients with APAs because of KCNJ5 mutations than in the wild-type group (Table 2) .
Patients with APAs because of ATPase mutations displayed higher PV plasma aldosterone concentrations compared with wild-type and CACNA1D groups (P<0.05). 11-Deoxycorticosterone and corticosterone concentrations were also significantly higher in these patients compared with those with APA because of CACNA1D mutations (P<0.05; Table 2 ).
Patients with APAs because of CACNA1D mutations had lower concentrations of aldosterone, corticosterone, and 11-deoxycorticosterone compared with all other groups combined together (P<0.05).
Discriminant Analyses
Using lateralization ratios normalized to adrenal cortisol levels (Table 1) , discriminant analyses showed that 50 of 79 cases (63%) were correctly classified ( Figure 1A ). However, normalization of lateralization ratios using DHEA+androstenedione (Table 1) improved prediction of mutations, with an increase (Table S2) . in correctly classified cases to 77% ( Figure 1B ). The correct prediction of underlying mutations or the absence of mutations was further improved to 95% by analyzing steroid concentrations (DHEA and DHEA-sulfate excluded) in the AV plasma from dominant and nondominant adrenals ( Figure 1C ). In particular, all APAs carrying CACNA1D and KCNJ5 mutations were correctly classified (100% sensitivity and specificity). We extended the discriminant steroid analysis to PV plasma with 7 steroids (aldosterone, 18-oxocortisol, 18-hydroxycortisol, 21-deoxycortisol, corticosterone, 11-deoxycorticosterone, and cortisol). Using these classifiers, the correct prediction of the associated mutations was 92% ( Figure 2 ). All APAs with mutations of ATPase genes and CACNA1D mutations were correctly grouped and only 1 APA with a KCNJ5 mutation was misclassified; most of the misclassified mutations (5 of the 6) were from the group of wild-type APA.
Discussion
The main finding of our study is that specific somatic mutations in APAs define distinct steroid profiles in AV plasma, which might reflect differences in the underlying biology of these tumors. Furthermore, the differences in steroid profiles in AV plasma translate to specific steroid signatures in PV plasma, potentially useful for determining the underlying APA genotype and selecting patients for AVS.
We tested the possible application of steroid profiling for APA genotype prediction by discriminant analyses on: (1) lateralization ratios of AVS plasma steroids, (2) steroid concentrations in AV plasma draining from both dominant and nondominant adrenals, and (3) PV plasma steroid concentrations. Discriminant analyses on dominant and nondominant AV plasma steroid concentrations gave the most accurate prediction of the underlying genotype and correctly classified 95% of the APA. However, the analysis of PV plasma steroids was also highly informative for genotyping patients with APA and correctly genotyped 92% of the APA (73 of 79). Most of the misclassified mutations (5 of the 6) were from the group of wild-type APA; the more heterogeneous steroid profiles within this group argues for the presence of as yet unidentified mutations that may result in a specific steroid secretion pattern.
The increased concentrations of the hybrid steroids, 18-hydroxycortisol, and 18-oxocortisol, in plasma samples from APA carrying a KCNJ5 mutation can be explained, in part, by the underlying biology of the APA that harbor these mutations. These APA display a predominantly zona fasciculata phenotype [15] [16] [17] [18] and are characterized by a distinct transcriptional fingerprint 19, 20 in contrast to APA with ATPase or CACNA1D mutations that display principally a zona glomerulosa phenotype.
16-18 Accordingly, APA harboring KCNJ5 mutations display higher expression levels of the zona fasciculata enzyme 11β-hydroxylase (CYP11B1) 17 and increased expression of CYP17A1. 15 This would result in an increased availability of 11-deoxycortisol which, in turn, is converted by CYP11B2 to 18-hydroxycortisol and 18-oxocortisol, 21 thereby resulting in the production of relatively high levels of these hybrid steroids compared with other APA.
Our data are consistent with this interpretation and other findings that expression of a KCNJ5 mutation in the HAC15 adrenal cell line resulted in a significant increase in CYP11B2 gene transcription and 18-oxocortisol production. 22 Furthermore, APAs carrying KCNJ5 mutations display an increased expression of CYP11B2 and CYP17A1 compared with those without known mutations. 15, 23, 24 We also demonstrate increased lateralization ratios for aldosterone and other steroids in patients with APAs carrying KCNJ5 mutations compared with other patients with APA. This is in agreement with the study of Seccia et al 25 , who reported an association of mutations in KCNJ5 with an elevated production of aldosterone and an increased lateralization ratio.
18-Oxocortisol has been reported previously as a potential biomarker for the subtyping of PA. 26, 27 In this study, we demonstrate that the concentration of 18-oxocortisol was markedly elevated in AV and PV plasma from patients with an APA harboring a KCNJ5 mutation. Therefore, the increased 18-oxocortisol levels in APA compared with BAH may reflect the predominant KCNJ5 mutation genotype in patients with APA in all populations, and reported as particularly prevalent in Japanese and Chinese populations. [28] [29] [30] [31] This may explain why the measurement of 18-oxocortisol by LC-MS/MS in PV plasma is especially useful for the differentiation of APA from BAH in a Japanese population.
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Strengths and Limitations of the Study
Strengths of the study are the strict clinical criteria to screen, diagnose and subtype PA and the postsurgical follow-up of patients to validate the successful clinical outcome of adrenalectomy. A limitation of the study is the small size of the study population, in particular, the number of patients with ATPase and CACNA1D mutations. A further limitation is the heterogeneity of the wild-type group of patients with APA that is likely to comprise as yet unidentified somatic mutations and the ATPase group that clusters together ATP1A1 and ATP2B3 mutations. The bicentric patient inclusion may also be seen as a limitation that, however, because of the small sample size of the Nijmegen group, is likely to have minimal impact on the steroid profiles of the wild-type and KCNJ5 steroid fingerprints (the largest groups) and no impact at all on the CACNA1D group (no Nijmegen patients). Notwithstanding these limitations, we have identified a steroid fingerprint in peripheral plasma that is strongly associated with APA genotype.
Perspectives
Steroid profiles in peripheral plasma can potentially predict the underlying genotype associated with unilateral PA. A multicenter prospective study is now being planned to confirm and extend these findings with the aim of translating them into clinical practice. Steroid APA genotype fingerprints could potentially be applied in a clinical setting to identify patients with APA from PV plasma that would serve to motivate both patient and clinician to undergo/perform the invasive and technically demanding procedure of AVS before adrenalectomy. What Is New?
• We determined steroid profiles in adrenal venous and peripheral venous plasma of genotyped patients with aldosterone-producing adenoma by liquid chromatography-tandem mass spectrometry.
• 18-Oxocortisol in lateralized adrenal venous and peripheral venous plasma is elevated in aldosterone-producing adenoma patients with a KCNJ5 mutation.
• Steroid profiles in adrenal venous and peripheral venous plasma are strongly associated with aldosterone-producing adenoma genotype.
What Is Relevant?
• Steroid profiles of peripheral plasma may predict genotype in unilateral primary aldosteronism.
Summary
The underlying genotype in unilateral primary aldosteronism is associated with a specific steroid fingerprint in adrenal and peripheral vein plasma. The quantity of antihypertensive drugs was expressed as Daily Defined Doses (DDD)
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Reference: ATC/DDD Index 2010: http://www.whocc.no/atc_ddd_index/ 2010.
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The study was approved by the appropriate institutional ethics committees and all patients 21 gave their written informed consent.
22
DNA sequencing of KCNJ5, ATP1A1, ATP2B3 and CACNA1D
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DNA fragments of KCNJ5, ATP1A1, ATP2B3 and CACNA1D were amplified by PCR and 24 sequenced as described. 4 The Although lateralization ratios are usually calculated by normalization to cortisol, other steroids 7 display larger adrenal venous to peripheral venous ratios in plasma concentrations and therefore 8 may be a superior alternative to cortisol for calculating lateralization of aldosterone production. 5 
9
DHEA + androstenedione are of interest because they are produced in the zona reticularis and 10 thereby are unaffected by co-production of glucocorticoids. comparisons. Chi-square and Fischer's exact tests were used to assess significance of differences 17 involving categorical data. Where differences were found to involve a specific group, the Wilcoxon 18 rank sum test was used to assess any difference for that group against all other groups combined. (P=0.01) at study entry compared to other groups combined.
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After unilateral adrenalectomy all except 3 patients in the wild type group displayed 34 decreases in ARRs to below cut-offs, but these 3 patients along with all others also had normal Table S3 ). The most conspicuous difference among groups was observed for 18-oxocortisol, which 6 showed 18-fold higher (P<0.001) concentrations in the venous drainage of dominant adrenals in 7 patients with APAs due to KCNJ5 mutations compared to all groups combined; differences also (Table S4 ). For the ATP1A1 and ATP2B3 groups, the median AV levels of pregnenolone, 
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Discriminant analyses
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Using the lateralization ratios normalized to cortisol ( 
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Normalization of lateralization ratios using DHEA + androstenedione (Table 1) improved 38 prediction of mutations, with an increase in correctly classified cases from 63% using cortisol as the 39 normalizer to 77% using DHEA + androstenedione ( Figure 1B in the venous drainages of adrenals with and without APAs ( Figure 1C) . In particular, all cases of 5 tumors due to CACNA1D and KCNJ5 mutations were correctly classified and no tumors were 6 misclassified with these mutations (100% sensitivity and specificity). For mutations of ATPase 7 genes, however, only 5 of 9 tumors were correctly classified and 4 tumors were incorrectly assigned 8 as wild type (56% sensitivity and 91% specificity). Areas under ROC curves varied from 0.944 for 9 tumors with mutations of ATPase genes to 1.000 for tumors with CACNA1D and KCNJ5 mutations.
10
We then extended the discriminant steroid analysis to peripheral plasma using seven steroids 
